Active Movers in Hot Line: Arena Pharmaceuticals (NASDAQ:ARNA), Advanced Micro Devices (NASDAQ:AMD)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) [Trend Analysis] retains strong position in active trade, as shares scoring -3.42% to $1.41 in a active trade session, while looking at the shares volume, around 3.48 Million shares have changed hands in this session. Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) reported that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health Surveillance Agency (ANVISA) for BELVIQ for chronic weight management.

BELVIQ is authorized in Brazil as an adjunct to a reduced-calorie diet and surged physical activity for chronic weight management in adult patients with a body mass index (BMI) of 30 kg/m2 or greater (obese), or overweight patients with a BMI greater than or equal to 27 kg/m2 in the presence of at least one weight-related comorbid condition such as high blood pressure, high cholesterol, cardiovascular disease, type 2 diabetes managed with oral hypoglycemic agents or sleep apnea.

The product is expected to become accessible following review by Brazil’s Medicines Market Regulation Board (CMED), which will trigger a $1 million milestone payment to Arena. The firm has institutional ownership of 50.50%, while insider ownership included 0.59%. ARNA attains analyst recommendation of 2.70 with week’s performance of 3.55%. Investors looking further ahead will note that the Price to next year’s EPS is 2.90%.

Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 2.72% to close at $10.95. The new Radeon Instinct GPU-based accelerators unveiled yesterday by chipmaker AMD are aimed at dramatically improving the capabilities of machine intelligence in server computing, the company said.

In addition to the new hardware, AMD also reported new software frameworks and a new open source library for GPU-based machine learning implementations. On top of yesterday’s news, AMD is presenting a live, online sneak preview of its long-awaited Zen CPU. With a new architecture built from the ground up, Zen could provide AMD with a greater competitive edge over Intel, the current giant of the microprocessor market. Moving forward to saw long-term intention, the experts calculate Return on Investment of -27.10%. The stock is going forward its fifty-two week low with 525.71% and lagging behind from its 52-week high price with -2.49%. AMD last month stock price volatility remained 5.40%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *